Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | New therapeutic directions in CTCL

Cutaneous T-cell lymphoma (CTCL) therapy has experienced a boost in recent times, such as the MAVORIC trial that led to the approval of mogamulizumab (NCT01728805). Here, Pierluigi Porcu, MD, Sidney Kimmel Cancer Center – Jefferson Health, discusses new therapeutic directions in CTCL. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.